Latest News

Novartis launches Prevacid

NOVELOS THERAPEUTICS CLOSES LAST TRANCHE IN $9 MILLION PRIVATE PLACEMENT

The European Commission grants Orphan Drug designation for NGR-hTNF in the treatment of hepatocellular carcinoma

IRONWOOD AND ASTELLAS ANNOUNCE JAPAN LICENSING AGREEMENT FOR LINACLOTIDE

New Phase IIa data on TMC435 in patients with hepatitis C presented at the ongoing AASLD - meeting

Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours

Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009

Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)

IRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM TWO PIVOTAL PHASE 3 TRIALS IN PATIENTS WITH CHRONIC CONSTIPATION

ORTHO CLINICAL DIAGNOSTICS LAUNCHES FETALSCREEN(TM) II FETAL MATERNAL HEMORRHAGE SCREENING TEST

More news... | RSS Feed...

Most Viewed

Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes

SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C

The European Commission grants Orphan Drug designation for NGR-hTNF in the treatment of hepatocellular carcinoma

Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours

IRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM TWO PIVOTAL PHASE 3 TRIALS IN PATIENTS WITH CHRONIC CONSTIPATION

New Phase IIa data on TMC435 in patients with hepatitis C presented at the ongoing AASLD - meeting

Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)

IRONWOOD AND ASTELLAS ANNOUNCE JAPAN LICENSING AGREEMENT FOR LINACLOTIDE

Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009

Clavis Pharma ASA receives USD 1.1 million Grant from Innovation Norway

Therapeutic Target

Cardiovascular

Dermatology

Endocrine and Metabolic

Gastroenterology

Genitourinary

Hematology

Immunology and Allergy

Infection

Musculoskeletal

Neurology

Obstetrics and Gynecology

Oncology

Ophthalmology

Psychiatry

Pulmonary

Categories

Deals and Alliances

Development

Financial Results

Financings

Intellectual Property

Regulatory

Press releases

Deals review

Headlines

PR Newswire